148 related articles for article (PubMed ID: 17874719)
1. [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer].
Petrović M; Tomić I; Ilić S
Vojnosanit Pregl; 2007 Aug; 64(8):525-9. PubMed ID: 17874719
[TBL] [Abstract][Full Text] [Related]
2. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
3. [Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results].
Tomić I; Petrović M; Plavec G; Ilić S
Vojnosanit Pregl; 2007 Sep; 64(9):591-6. PubMed ID: 17969813
[TBL] [Abstract][Full Text] [Related]
4. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
7. Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer.
Petrovic M; Tomic I; Plavec G; Ilic S; Ilic N; Baskic D
J BUON; 2008; 13(1):93-6. PubMed ID: 18404793
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
11. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
12. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
13. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
16. Expression of neuroendocrine markers in non-small cell lung cancer.
Sørhaug S; Steinshamn S; Haaverstad R; Nordrum IS; Martinsen TC; Waldum HL
APMIS; 2007 Feb; 115(2):152-63. PubMed ID: 17295682
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
18. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
19. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in 32 cases of so-called sclerosing hemangioma of the lung: identified by immunohistochemical and ultrastructural study.
Xu HM; Li WH; Hou N; Zhang SG; Li HF; Wang SQ; Yu ZY; Li ZJ; Zeng MY; Zhu GM
Am J Surg Pathol; 1997 Sep; 21(9):1013-22. PubMed ID: 9298877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
